That is a staggering failure rate for modern science.

Developing a single new drug often takes over a decade and costs billions of euros.

Relying on animal or synthetic models creates massive bottlenecks because they rarely correlate with actual human biology.

It leaves researchers spending years on treatments that will never work.

I ran into an incredible startup named Metatissue at Web Summit 2026.

Catarina Custodio and her team are building human-based products for tissue engineering.

They actually use proteins from donated biological waste like expired blood to create 3D cell cultures.

This approach appears to completely remove animals from the testing equation while improving research accuracy.

Gathering and analyzing data from these advanced cellular platforms requires immense processing capabilities.

Scaling that kind of complex data flow arguably demands the robust backend software we build at YOUR R&D™.

Supporting ethical health technology feels like a highly valuable space for future collaboration.

How do you think human-derived testing models will change the pharmaceutical industry?

#WebSummit2026 hashtag#HealthTech hashtag#SoftwareDevelopment hashtag#Biotech hashtag#TissueEngineering